Boston Scientific Corp (NYSE: BSX) closed at around $78.44 per share on Wednesday, marking an intraday decline of more than 10% amid heavy trading following its latest quarterly earnings and guidance update.
Market Capitalization
At Wednesday’s close, Boston Scientific’s market capitalization stood at approximately $136 billion.
Quarterly Results
For the fourth quarter ended December 31, 2025, Boston Scientific reported consolidated net sales of $5.286 billion, up 15.9% on a reported basis and 12.7% on an organic basis compared with the year-ago period. The company’s GAAP net income attributable to common shareholders was $672 million, or $0.45 per share, and it delivered adjusted earnings of $0.80 per share, compared with $0.70 per share a year earlier.
Segment revenue performance for the quarter included growth across reportable businesses. MedSurg net sales rose 11.7% on a reported basis while Cardiovascular revenue increased 18.2% on a reported basis versus the prior year.
Full-Year Results Context
For the full year 2025, Boston Scientific reported net sales of $20.074 billion, up 19.9% on a reported basis and 15.8% on an organic basis compared with 2024. GAAP net income was $2.898 billion, or $1.94 per share, compared with $1.853 billion, or $1.25 per share, in 2024. Adjusted EPS for the year was $3.06, up from $2.51 in the prior year.
Business & Operations Update
During the quarter, Boston Scientific noted FDA approval and CE Mark receipt for its FARAPOINT Pulsed Field Ablation (PFA) Catheter, a focal PFA catheter capable of creating focal and linear lesions with a single device. It also reported U.S. coverage for Endoscopic Sleeve Gastroplasty (ESG) using the OverStitch Endoscopic Suturing System beginning December 18, 2025, and recognition of ESG by the American Society for Metabolic and Bariatric Surgery as an endorsed procedure.
In 2025, the company incurred restructuring and related net charges associated with the discontinuation of sales of the ACURATE neo2 and ACURATE Prime Aortic Valve Systems, with these charges excluded from its adjusted performance measures.
M&A and Strategic Moves
Boston Scientific agreed to acquire Penumbra, Inc. in a transaction valued around $14.5 billion financed with a combination of cash and stock. Penumbra is expected to operate within Boston Scientific’s cardiovascular segment upon closing later in 2026.
Equity Analyst Commentary
Institutional research sources noted that Boston Scientific’s Q4 earnings and revenue slightly exceeded consensus expectations, with adjusted EPS above the analyst consensus of $0.78 per share and revenue marginally above forecasts. However, observers also reported that shares declined sharply in response to the firm’s cautious revenue growth outlook for 2026.
Guidance & Outlook
Boston Scientific issued guidance for fiscal 2026 that anticipates organic revenue growth of approximately 10%–11% and adjusted earnings per share in a range of $3.43 to $3.49, with first-quarter EPS expected between $0.78 and $0.80. The company expects organic sales growth to moderate from 2025 levels.
Regulatory and industry context includes ongoing adoption of minimally invasive procedures and continued approvals of interventional devices, factors the company has highlighted as areas to watch for future performance.
Performance Summary
Boston Scientific’s stock declined sharply on Wednesday following its Q4 report and 2026 outlook. Fourth-quarter revenue grew double-digit year-over-year to approximately $5.29 billion, with adjusted EPS rising to $0.80. Full-year sales and earnings increased from 2024 levels, and the acquisition of Penumbra represents a significant strategic investment. Future growth will be shaped by product approvals and the integration of recent acquisitions.